The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
Netflix's Vladimir stars Rachel Weisz as a 56-year-old consumed by desire, echoing a secret midlife libido explosion many women are experiencing. Attributed to surging HRT use and GLP-1 weight loss injections, this trend is reshaping confidence and relationships. From cultural hits to real-life chats, explore why midlife women feel hotter than ever.
The Indian government has issued a strict advisory cautioning pharmaceutical companies against surrogate advertising to promote GLP-1 drugs, amid fears of consumer misuse. Signed by Drugs Controller General Rajeev Singh Raghuvanshi on March 10, the note prohibits all direct or indirect promotions on any platform. This comes as Ozempic and Wegovy patents near expiry, potentially flooding the market with generics.
Semaglutide, the powerhouse behind Ozempic and Wegovy, might soon become dramatically more affordable. A recent study reveals generic versions could cost as little as $28 per person-year after patents expire in 2026. This could transform access to treatment for obesity and type 2 diabetes globally.
An observational study in the British Medical Journal reveals GLP-1 medications like semaglutide significantly lower substance use disorder (SUD) risk in US veterans with type 2 diabetes. Compared to SGLT2 inhibitors, GLP-1s reduced new addiction risks by up to 25% and improved outcomes like 50% fewer substance-related deaths. These findings challenge traditional views on addiction and metabolic health.
Hims & Hers made waves with a Super Bowl ad promoting preventive care through tailored prescriptions and peptides for everyday Americans. But announcing compounded oral semaglutide triggered an FDA investigation and a swift lawsuit from Novo Nordisk. The quick settlement highlights battles over GLP-1 access and drug pricing.
A new peer-reviewed study from Mount Sinai researchers has created the first sex-specific atlas of GLP-1 expression in the mouse brain, revealing dramatic differences between males and females. These insights into drugs like semaglutide and liraglutide could reshape treatments for obesity, diabetes, and even psychiatric disorders. Key hindbrain and olfactory bulb variations highlight why GLP-1 effects on appetite and weight loss differ by sex.
Contrary to predictions, chocolate sales are surging among GLP-1 weight-loss drug users in the U.S., according to Swiss chocolatier Lindt & Spruengli. An internal analysis reveals these households account for 17.5% of chocolate purchases, with premium varieties rising nearly 17%. This challenges assumptions about appetite suppression from drugs like Ozempic and Mounjaro.
Independent health platform Healthier Happy has chosen CoreAge Rx as its preferred destination for tirzepatide online, highlighting its physician-supervised telehealth model, straightforward pricing, and direct-to-home delivery. This recognition underscores CoreAge Rx's role in simplifying access to GLP-1 therapies like tirzepatide and semaglutide for metabolic health.
Burn Slim Capsules are gaining attention as a natural GLP-1 mimetic alternative to prescription drugs like semaglutide. Real users report dramatic appetite changes, consistent fat loss up to 22 pounds in 12 weeks, and sustained results without muscle loss or loose skin. Backed by studies on its four key ingredients, this guide exposes the science and user truths.
